Menu
Home
TMU
Sitemap
FAQ
Links
Online Portals
TMU Online Resources
External Online Resources
Affiliated Hospitals
REACTA
TCTI 2025
正體中文
Search
News
News
Announcements
Government
Events
Business
Charges
About OHR
About OHR
OHR Overview
Dean
OHR Members
Department
JIRB Administration Section
Data Safety Managing Section
Joint Clinical Research Center
Joint Biobank
Business
Business
Clinical Trial
Clinical Trial Agreement
Investigator-Initiated Trial
Project Writing Consultation
Ongoing Clinical Trials
Biobank
Biobank Application
Number of Specimen and Omic Data
Participant Rights and Complaint Procedures
TMU-JIRB
TMU-JIRB
About TMU-JIRB
Introduction
Administrative Staff
Members
SOP
Application Forms
IRB Submission
Charges
Meeting Date
Meeting Minutes
FAQs
Download
Download
Form
Clinical Trial
Regulation
TMU Regulation
Domestic Regulation
Related Regulation
System
ATM system
Contact
Contact
Contact Info
Website Feedback Form
Home
Ongoing Clinical Trials
Ongoing Clinical Trials
Institution
All
SHH
Principal Investigator
All
Chen Kuan-Yuan
Chia-Lun Chou
CHIH-HWA CHEN
Chih-Hwa Chen
Hou-Chang Chiu
Kang-Yun Lee
Lung Chan
Mai-Szu Wu
Ming-Yao Chen
Po-Hao Feng
Tsu-Yi Chao
Tzu-Tao Chen
Wei-Hong Cheng
Woan-Ruoh Lee
Yao-Yu Hsieh
Yu-kai Su
Yu-Sheng Chang
Yung-Ho Hsu
YUNG-HO HSU
Protocol Title
Keyword
Search
Clear
TMU-JIRB No.
Protocol Title
Institution / Principal Investigator
dictionary.testing.TypeOfStudy
dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202011026
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer
SHH / Kang-Yun Lee
N202012007
A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)
SHH / Kang-Yun Lee
N202012035
Development of stem cell culture technology in vitro - Hair follicle and skin sample collection
SHH / Woan-Ruoh Lee
N202012037
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
SHH / Wei-Hong Cheng
N202101017
Non-Interventional Collecting Evidences For ILD in Taiwan: Optimized Novel Therapy
SHH / Tzu-Tao Chen
N202102065
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
SHH / Tsu-Yi Chao
N202102073
Prospective Observational Cohort Study of Patients with Moderate to Severe Chronic Plaque Psoriasis in Taiwan
SHH / Woan-Ruoh Lee
N202104068
A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients with Advanced Solid Malignancies
SHH / Wei-Hong Cheng
N202108070
An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)
SHH / Kang-Yun Lee
N202110016
A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis
SHH / Yu-Sheng Chang
1
2
3
4
5
6
/
6
TOP